Ascendis Pharma A/S (NASDAQ:ASND) Receives Equal Weight Rating from Morgan Stanley

Morgan Stanley restated their equal weight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in a research report report published on Monday morning, Benzinga reports. Morgan Stanley currently has a $109.00 price objective on the biotechnology company’s stock. Several other equities research analysts also recently weighed in on ASND. 3M reaffirmed a […]

Related Keywords

Wellington ,New Zealand General ,New Zealand ,Ascendis Pharma ,Goldman Sachs Group Inc ,Wellington Management Group ,Morgan Stanley ,Avoro Capital Advisors ,Franklin Resources Inc ,Cantor Fitzgerald ,T Rowe Price Investment Management Inc ,Free Report ,Moderate Buy ,Management Group ,Capital Advisors ,Rowe Price Investment Management ,Sachs Group ,Franklin Resources ,Get Free Report ,Transcon Growth Hormone ,Transcon Parathyroid Hormone ,Transconc Type ,Ascendis Pharmaa S ,Nasdaq Asnd ,Wasnd ,Medical ,Reiterated Rating ,